Injectpower

What Injectpower does

Injectpower is a French deeptech startup founded in 2020 that designs and manufactures ultra-miniature solid-state lithium-ion microbatteries for implantable medical devices. The company is headquartered in Moirans, France, with additional operations in Grenoble, France (where a 200mm MEMS production facility is planned for 2026) and Emeryville, California. Its technology originates from more than 16-20 years of research at CEA-Leti and is protected by a portfolio of over 40 patents, with cumulative production exceeding one million microbatteries on a validated 200mm semiconductor supply chain. The batteries are as thin as a human hair, deliver energy densities reportedly 5-10 times greater than current commercial alternatives, are wirelessly rechargeable, and are designed for thousands of charge cycles and decades of operation inside the body.

The company's core product targets medical device manufacturers building smart implantables for continuous monitoring, ultra-low electro-stimulation, and short-term surgical vital-signs tracking. Currently named applications include Injectsense's iOP-Connect continuous intraocular pressure monitor for glaucoma management and an intracranial pressure and flow sensor integrated into neurosurgical shunts, the former of which received FDA Breakthrough Device Designation and entered first-in-human studies in 2023. Injectpower monetizes through direct B2B component sales to OEMs and through licensing of its battery technology, with custom pricing tied to specifications such as size, capacity, and integration requirements, and multi-year contracts typical.

Injectpower raised a €6.5 million seed round in October 2023 led by IDEC Group with participation from Bpifrance and French Silicon Valley business angels, followed by an €8.7 million France 2030 grant in November 2024 to fund construction of an advanced production facility. The leadership team combines deep battery materials expertise from former CEA-LETI R&D lab manager and CTO Raphaël Salot with commercialization experience from CEO Philippe Andreucci, who has previously raised more than €30M for deeptech ventures.

Name

Injectpower

Legal name

Injectpower

Website

https://injectpwr.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Injectpower is a French deeptech startup that designs ultra-miniature solid-state lithium-ion microbatteries for implantable medical devices, selling components and licenses to medical device OEMs such as Injectsense for glaucoma and neurosurgery applications.

Ownership category

akta.pro rank

Product category

Microbatteries for medical implants

NAICS

Battery Manufacturing (33591), Battery Manufacturing (335910)

SIC

Electronic & Other Electrical Equipment (No Computer Equip) (3600)

akta.pro primary industry

Solid-State Battery Materials & Cell Manufacturing (EUAFABAH)

akta.pro secondary industries

Battery Cells (Li-ion, LFP, Sodium-ion, Lead-acid, NiMH) (IMAGAHAA), Battery Pack Manufacturing & Module Assembly (EUAFABAI)

Keywords

• Microbattery technology
• Solid-state batteries
• Implantable medical devices
• Energy storage components
• Medical microbatteries

Headquarters

HQ city

Chêne Gautier

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations

Revenue model

1. Microbattery Hardware Sales: Direct sale of ultra-miniature solid-state microbatteries to medical device manufacturers for integration into implantable medical devices. Revenue generated through component sales to partners like Injectsense and other medtech companies.
2. Technology Licensing: Licensing of proprietary battery technology and patents to medical device manufacturers. The company was founded based on 20 years of technology development at CEA and more than 40 patents, which can be licensed to partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Injectpower designs, develops and manufactures ultra-miniature rechargeable solid-state lithium-ion microbatteries for implantable medical devices. Built using thin-film and semiconductor processes on a 200mm microelectronic supply chain, the batteries offer energy densities 5 to 10 times greater than current commercial alternatives, decades of operation, wireless recharging, and customization for medical implant applications including continuous intraocular pressure monitoring, intracranial pressure measurement, and cardiac devices. The company also licenses its patented microbattery technology (40+ patents) originally developed at CEA-Leti.

Product overview

Injectpower is a developer and manufacturer of ultra-miniature solid-state microbatteries specifically designed for implantable medical devices. The company's core product is its rechargeable microbattery technology, which enables devices to operate autonomously as sensors or actuators that collect data continuously for extended periods. The battery offerings are complemented by the iOP-Connect application (developed with partner Injectsense), which provides continuous intraocular pressure monitoring for glaucoma patients. All products are developed using a validated semiconductor supply chain with over 16 years of research and more than 40 patents, and are manufactured using 200mm MEMS fabrication processes.

Differentiator

Problem solved

Functional benefit

Products and services

• Ultra-Miniature Rechargeable Microbatteries Rechargeable solid-state lithium-ion microbatteries designed for implantable medical devices, offering 5-10x greater energy density than current commercial alternatives, high reliability, thousands of cycle lifetime and wireless recharging capability. Customized for size, capacity, interconnect and integration requirements and sold to medical device manufacturers.
• Microbattery Technology Licensing Licensing of Injectpower's proprietary microbattery technology and patent portfolio (40+ patents) developed at CEA to medical device manufacturers and partners for integration into their own implantable products.

Quantifiable outcome

• Energy densities 5 to 10 times greater than current commercial capability
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core, flagship and minor.

• CEA-LeticoreTechnology or IntegrationCEA-Leti is the technology origin partner for Injectpower. The company was founded based on 20 years of technology development at CEA, and Injectpower licenses technology from CEA-Leti. CEA-Leti developed the microbattery technology that Injectpower commercializes. The partnership provides ongoing support through a pre-commercial 200mm microelectronic supply chain.
• InjectsenseflagshipStrategic or Co-development PartnerInjectsense is Injectpower's first American medtech partner, developing implantable pressure measuring systems for glaucoma monitoring and neurosurgery. Injectpower supplies microbatteries for Injectsense's iOP-Connect device. The Injectsense glaucoma solution received FDA Breakthrough Device Designation. First-in-human studies began in 2023 with additional studies ramping up in 2024.
• Auvergne-Rhône-Alpes RegionminorOthersRegional government partner supporting Injectpower's operations in the Grenoble area. Logo appears on partners page indicating some form of regional support or collaboration.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Cymbet Corporation: Cymbet manufactures solid-state thin-film lithium-ion microbatteries for medical implants, IoT sensors, and energy harvesting applications — the closest direct competitor to Injectpower in solid-state thin-film microbatteries for medical devices.
• Ilika plc: UK-based Ilika develops solid-state microbattery technology (Stereax) for medical implants and IoT, using thin-film processes on semiconductor wafer lines — directly comparable to Injectpower's solid-state microbattery approach for implantables.
• Enfucell Oy: Finnish Enfucell produces thin-film printed batteries for healthcare, logistics, and IoT sensors. Their flexible/printed microbattery technology overlaps with Injectpower's miniaturized, application-specific microbattery value proposition.
• Front Edge Technology: Front Edge Technology develops thin-film solid-state lithium batteries for medical, IoT, and consumer applications. Like Injectpower, they target ultra-thin form factors and high reliability for regulated medical use cases.
• BrightVolt: BrightVolt manufactures thin-film flexible lithium polymer batteries for medical, IoT, and smart packaging. They compete in the same ultra-thin rechargeable microbattery category as Injectpower.

Emerging players

• Imprint Energy: Imprint Energy develops zinc-based printed batteries for sensors, wearables, and medical devices. They overlap with Injectpower in low-power medical sensors but use a different chemistry, making them an adjacent emerging player.

Broad incumbents

• ProLogium Technology: ProLogium is a leading solid-state battery developer primarily targeting EV applications. While at much larger scale and different end market, they are a relevant incumbent in solid-state battery technology that could eventually move down-market into medical.
• Murata Manufacturing: Murata (including its acquired Sony battery business) is a broad incumbent supplying small-format lithium-ion batteries to medical and IoT OEMs. They compete on supply chain reliability and scale rather than microbattery IP specialization.
• STMicroelectronics: STMicroelectronics is a broad semiconductor incumbent with energy-harvesting and battery-management product lines serving medical and IoT. They are not a microbattery manufacturer but represent the kind of scale player that could integrate or compete with Injectpower's technology.

Others

• CEA-Leti: CEA-Leti is the French government research institute that originally developed Injectpower's microbattery IP. They are an enabling technology partner (and ongoing licensor) rather than a competitor, but represent a comparable R&D platform that could spawn competing deeptech spinouts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wix-com

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Injectpower